Taking stock of the drug industry, from the lab to the medicine chestOctober 9, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Kevin Dietsch/Getty Images STAT+ | Major PBMs ask judge to remove Lina Khan from FTC's insulin-price lawsuit The legal effort from UnitedHealth, CVS, and Cigna is an escalation in the PBMs' campaign to undermine Khan and the FTC investigation. By Bob Herman STAT+ | Q&A: How the FDA is approaching AI in clinical trials and drug development The Food and Drug Administration's Tala Fakhouri discusses the federal agency's approach to the regulation of AI in clinical trials. By Katie Palmer STAT+ | GSK to pay up to $2.2 billion to settle most Zantac lawsuits over claims the heartburn pill causes cancer The settlement covers roughly 80,000 cases, or 93% of the suits that were outstanding in state courts around the U.S. By Ed Silverman Adobe STAT+ | Eli Lilly, Insitro ink a new kind of AI drug development deal Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. By Brittany Trang STAT+ | As U.S. efforts stall, China pushes ahead with CRISPR treatments for muscular dystrophy Two Chinese biotechs are testing gene editing in boys with Duchenne muscular dystrophy, even as projects at U.S. companies like Vertex have slowed. By Jason Mast More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments